Want to see HK:2273 full AI Analyst Report?
Top Page
Gushengtang Holdings Limited
(2273)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$32.00
▲(21.03% Upside)
Action:Reiterated
Date:08/29/26
The score is driven primarily by strong financial performance (sustained profitability since 2022 and rapid recent revenue growth), supported by a favorable valuation (moderate P/E and solid dividend yield). Technicals are constructive on trend (price above major moving averages) but tempered by mixed momentum signals (negative MACD).
Positive Factors
Rapid Revenue Growth
Sustained, accelerating revenue growth indicates strong patient demand and expanding clinic activity. Continued top-line momentum can support operating scale and reinforce Gushengtang’s position in China’s TCM healthcare services market over the medium term.
Negative Factors
Weaker Free Cash Flow Growth
Although free cash flow remains positive and supported by earnings, the sharp 2025 contraction signals weaker cash conversion momentum. If sustained, this could limit internally funded expansion and increase reliance on debt or other financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Sustained, accelerating revenue growth indicates strong patient demand and expanding clinic activity. Continued top-line momentum can support operating scale and reinforce Gushengtang’s position in China’s TCM healthcare services market over the medium term.
Read all positive factors
Gushengtang Holdings Limited (2273) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.46B
Dividend Yield3.85%
Average Volume (3M)766.20K
Price to Earnings (P/E)12.9
Beta (1Y)1.24
Revenue Growth11.78%
EPS Growth34.19%
CountryHK
Employees4,214
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.83
Shares Outstanding234,371,050
10 Day Avg. Volume1,014,715
30 Day Avg. Volume766,196
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.83
Price to Sales (P/S)1.89
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.95Price Target Upside54.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.85
Revenue Forecast (FY)HK$3.72B
Gushengtang Holdings Limited Business Overview & Revenue Model
Company Description
Gushengtang Holdings Limited, an investment holding company, provides healthcare services in the People’s Republic of China. The company offers consultation, traditional massage, moxibustion, acupuncture, and other therapies. It is also involved i...
How the Company Makes Money
Gushengtang primarily generates revenue through its TCM healthcare service operations. Key revenue streams include: (1) Medical consultation and outpatient service fees: income earned when patients visit Gushengtang’s TCM clinics for physician con...
Gushengtang Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
69
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.41B | 3.25B | 3.02B | 2.32B | 1.62B | 1.37B |
| Gross Profit | 1.06B | 1.01B | 909.35M | 700.00M | 499.54M | 620.30M |
| EBITDA | 501.90M | 485.74M | 375.05M | 429.90M | 324.22M | -62.75M |
| Net Income | 421.83M | 352.76M | 306.78M | 252.20M | 180.85M | -507.07M |
Balance Sheet | ||||||
| Total Assets | 4.36B | 3.99B | 3.66B | 3.38B | 2.61B | 2.39B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.15B | 1.14B | 1.33B | 1.02B | 1.03B |
| Total Debt | 1.53B | 784.51M | 508.56M | 370.57M | 351.29M | 345.37M |
| Total Liabilities | 2.47B | 1.81B | 1.28B | 1.07B | 891.49M | 842.39M |
| Stockholders Equity | 1.88B | 2.17B | 2.38B | 2.30B | 1.72B | 1.55B |
Cash Flow | ||||||
| Free Cash Flow | 274.68M | 482.65M | 361.77M | 332.41M | 244.02M | 138.03M |
| Operating Cash Flow | 326.86M | 582.57M | 452.37M | 410.14M | 281.00M | 187.75M |
| Investing Cash Flow | -150.11M | -352.40M | -267.37M | -263.61M | -178.36M | -48.95M |
| Financing Cash Flow | -421.09M | -442.38M | -375.19M | 157.50M | -138.08M | 638.57M |
Gushengtang Holdings Limited Technical Analysis
Neutral
26.44
Price Trends
28.33
Negative
27.76
Negative
27.94
Negative
Market Momentum
-0.24
Negative
50.08
Neutral
23.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2273, the sentiment is Neutral. The current price of 26.44 is below the 20-day moving average (MA) of 27.18, below the 50-day MA of 28.33, and below the 200-day MA of 27.94, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 50.08 is Neutral, neither overbought nor oversold. The STOCH value of 23.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2273.
Gushengtang Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.46B | 12.90 | 20.84% | 3.85% | 11.78% | 34.19% | |
67 Neutral | HK$1.08B | 10.39 | 5.57% | 2.29% | 4.75% | ― | |
65 Neutral | HK$4.38B | 10.91 | 33.37% | 4.09% | 16.70% | 38.98% | |
62 Neutral | HK$6.54B | 31.44 | 2.50% | 0.39% | 1.59% | -58.55% | |
56 Neutral | HK$1.22B | 85.71 | 0.48% | 1.02% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.03B | 31.34 | 1.27% | ― | ― | ― |
* Healthcare Sector Average
HK:2273
Gushengtang Holdings Limited
26.98
-5.40
-16.68%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
17.61
-17.20
-49.41%
HK:3309
C-MER Eye Care Holdings Limited
0.89
-0.98
-52.43%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-30.16%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.36
-4.17
-28.70%
HK:6639
Arrail Group Ltd.
1.83
-0.45
-19.78%
Gushengtang Holdings Limited Corporate Events
Gushengtang’s Interim Profit Jumps on Double-Digit Revenue Growth
Aug 28, 2026
Gushengtang Holdings Limited reported solid interim results for the six months ended June 30, 2026, with group revenue rising 10.6% year-on-year to RMB1.65 billion and gross profit up 9.7% to RMB502.1 million. The company also recorded a 39.8% inc...
Gushengtang Declares HK$1.15 Interim Dividend for First Half of 2026
Aug 28, 2026
Gushengtang Holdings Limited has declared an interim ordinary dividend of HK$1.15 per share for the six months ended June 30, 2026, for the financial year ending December 31, 2026. The dividend will be paid in Hong Kong dollars without withholding...
Gushengtang Expands Malaysian TCM Network with Three Clinic Acquisitions
Aug 27, 2026
Gushengtang Holdings Limited has agreed, via its Malaysian subsidiary, to acquire 100% equity interests in YC TCM (Taman Segar) Sdn. Bhd., YC TCM Sdn. Bhd. and SWS Medical Sdn. Bhd., all of which provide traditional Chinese medicine consultation a...
Gushengtang Sets Board Meeting to Review Interim Results and Dividend
Aug 18, 2026
Gushengtang Holdings Limited has scheduled a board meeting for August 28, 2026, to review and approve the group’s unaudited interim results for the six months ended June 30, 2026 and to decide on their publication. The meeting will also cons...
Gushengtang Delays Final Dividend Payout to July 30
Jul 19, 2026
Gushengtang Holdings Limited has announced a change to the payment schedule for its previously approved final dividend of HK$0.69 per share for the year ended December 31, 2025. The company said external institutions responsible for processing the...
Gushengtang Updates Payment Date for HKD 0.69 Final Dividend
Jul 19, 2026
Gushengtang Holdings Limited has declared a final ordinary cash dividend of HKD 0.69 per share for the financial year ended 31 December 2025, following shareholder approval on 18 June 2026, with an ex-dividend date of 24 June and record date of 30...
Gushengtang to Acquire Two Beijing Traditional Chinese Medicine Hospitals
Jul 5, 2026
Gushengtang Holdings’ subsidiary Beijing Gushengtang Health Management Co., Ltd. has agreed to acquire controlling interests in Beijing Changping District Shahe Integrated Traditional Chinese and Western Medicine Hospital and Beijing Hongyan...
Gushengtang accelerates TCM expansion with clinic acquisitions in Singapore and Tianjin
Jun 23, 2026
Gushengtang Holdings is expanding its traditional Chinese medicine footprint through strategic acquisitions in Singapore and Tianjin. The company’s subsidiary in Singapore has agreed to acquire 100% equity interests in Sante Wellness TCM Cli...
Gushengtang Shareholders Approve All AGM Resolutions and 2025 Final Dividend
Jun 18, 2026
Gushengtang Holdings Limited reported that all resolutions at its June 18, 2026 annual general meeting in Guangzhou were approved by shareholders via poll, including adoption of the 2025 audited financial statements and re-election of all proposed...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.